Hsu KC - Search Results

1

USP24 promotes drug resistance during cancer therapy.

Wang SA, Young MJ, Wang YC, Chen SH, Liu CY, Lo YA, Jen HH, Hsu KC, Hung JJ. Wang SA, et al. Among authors: hsu kc. Cell Death Differ. 2021 Sep;28(9):2690-2707. doi: 10.1038/s41418-021-00778-z. Epub 2021 Apr 12. Cell Death Differ. 2021. PMID: 33846536 Free PMC article.

2

The role of ubiquitin-specific peptidases in cancer progression.

Young MJ, Hsu KC, Lin TE, Chang WC, Hung JJ. Young MJ, et al. Among authors: hsu kc. J Biomed Sci. 2019 May 27;26(1):42. doi: 10.1186/s12929-019-0522-0. J Biomed Sci. 2019. PMID: 31133011 Free PMC article. Review.

3

USP24-i-101 targeting of USP24 activates autophagy to inhibit drug resistance acquired during cancer therapy.

Young MJ, Wang SA, Chen YC, Liu CY, Hsu KC, Tang SW, Tseng YL, Wang YC, Lin SM, Hung JJ. Young MJ, et al. Among authors: hsu kc. Cell Death Differ. 2024 Mar 15. doi: 10.1038/s41418-024-01277-7. Online ahead of print. Cell Death Differ. 2024. PMID: 38491202

4

An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells.

Chao MW, Huang HL, HuangFu WC, Hsu KC, Liu YM, Wu YW, Lin CF, Chen YL, Lai MJ, Lee HY, Liou JP, Teng CM, Yang CR. Chao MW, et al. Among authors: hsu kc. Oncotarget. 2017 Apr 25;8(17):27772-27785. doi: 10.18632/oncotarget.15115. Oncotarget. 2017. PMID: 28186963 Free PMC article.

5

Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer.

Chen CH, Changou CA, Hsieh TH, Lee YC, Chu CY, Hsu KC, Wang HC, Lin YC, Lo YN, Liu YR, Liou JP, Yen Y. Chen CH, et al. Among authors: hsu kc. Clin Cancer Res. 2018 Mar 1;24(5):1176-1189. doi: 10.1158/1078-0432.CCR-17-2066. Epub 2017 Dec 8. Clin Cancer Res. 2018. PMID: 29222162

6

A Novel Dual HDAC6 and Tubulin Inhibitor, MPT0B451, Displays Anti-tumor Ability in Human Cancer Cells in Vitro and in Vivo.

Wu YW, Hsu KC, Lee HY, Huang TC, Lin TE, Chen YL, Sung TY, Liou JP, Hwang-Verslues WW, Pan SL, HuangFu WC. Wu YW, et al. Among authors: hsu kc. Front Pharmacol. 2018 Mar 13;9:205. doi: 10.3389/fphar.2018.00205. eCollection 2018. Front Pharmacol. 2018. PMID: 29593536 Free PMC article.

7

A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo.

Wu YW, Chao MW, Tu HJ, Chen LC, Hsu KC, Liou JP, Yang CR, Yen SC, HuangFu WC, Pan SL. Wu YW, et al. Among authors: hsu kc. Oncogenesis. 2021 May 13;10(5):39. doi: 10.1038/s41389-021-00331-0. Oncogenesis. 2021. PMID: 33986242 Free PMC article.

8

Structure-based virtual screening discovers novel kidney-type glutaminase inhibitors.

Lin LC, Chang HY, Lin TE, Lin JR, Hsia SM, Hsu KC, Huang TC. Lin LC, et al. Among authors: hsu kc. Biomed Pharmacother. 2022 Oct;154:113585. doi: 10.1016/j.biopha.2022.113585. Epub 2022 Aug 24. Biomed Pharmacother. 2022. PMID: 36029536 Free article.

9

Parallel screening of wild-type and drug-resistant targets for anti-resistance neuraminidase inhibitors.

Hsu KC, Hung HC, Horng JT, Fang MY, Chang CY, Li LT, Chen IJ, Chen YC, Chou DL, Chang CW, Hsieh HP, Yang JM, Hsu JT. Hsu KC, et al. Among authors: hsu jt. PLoS One. 2013;8(2):e56704. doi: 10.1371/journal.pone.0056704. Epub 2013 Feb 20. PLoS One. 2013. PMID: 23437217 Free PMC article.

10

Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells.

Wu WC, Liu YM, Liao YH, Hsu KC, Lien ST, Chen IC, Lai MJ, Li YH, Pan SL, Chen MC, Liou JP. Wu WC, et al. Among authors: hsu kc. Eur J Med Chem. 2020 Oct 1;203:112540. doi: 10.1016/j.ejmech.2020.112540. Epub 2020 Jul 16. Eur J Med Chem. 2020. PMID: 32683166

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

533 results

Search Page